Business
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 9, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:
About this update from Sutro Biopharma, Inc.
[{"type":"text","content":"Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\n\n\nSOUTH SAN FRANCISCO, Calif., Aug. 9, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the appointment of Jane Chung to the newly-created position of Chief Commercial Officer, effective August 9, 2021. \nMs. Chung will provide patient, provider, thought leader, and reimbursement insights as Sutro's clinical programs advance. Ms. Chung will envision and lead an emerging commercial focus within Sutro, including engagement of the various oncology communities and stakeholders as well as planning for sales, marketing, and market access functions for the company. Ms. Chung has more than 20 years of pharmaceutical and biotechnology experience, most recently having served as President of AstraZeneca Canada, as well as previous roles at Onyx Pharmaceuticals and Genentech and is a registered pharmacist.\n\"The addition of Jane to Sutro's leadership team is crucial as we prepare for key milestones in our programs, including the continued development of STRO-002, our FolRα targeting ADC and STRO-001, our CD-74 targeting ADC\" said Bill Newell, Chief Executive Officer of Sutro. \"Jane has a proven track record of setting commercial strategies and in shepherding products from clinical to commercial stage. We look forward to working with Jane as Sutro continues to deliver critical therapies to patients with cancer.\"\nJane Chung added, \"I am incredibly excited to be joining Sutro to support the strategic planning of commercializing the pipeline and advancing the science. Sutro's unique technology platform designed to develop next-generation cancer treatments with speed and scale is highly differentiated, and when combined with its innovative science and entrepreneurial culture, can potentially transform standard of care for cancer patients and improve their lives.\" \nAs President of AstraZeneca Canada, Ms. Chung led all commercial functions within a broad pipeline of Oncology, Respiratory, Immunology, Cardiology, Renal and Metabolism therapeutic areas. Prior, she was Vice President and Head of AstraZeneca's U.S. Immuno-Oncology franchise, and...